Latest News for: bladder cancer

Edit

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

The Galveston Daily News 16 May 2026
AUSTIN, Texas--(BUSINESS WIRE)--May 15, 2026-- ....
Edit

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

The Galveston Daily News 16 May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 15, 2026-- ....
Edit

Studies Highlight Advances in Bladder Cancer Care and Emerging Environmental Risks

Killeen Daily Herald 16 May 2026
WASHINGTON, DC, May 15, 2026 (GLOBE NEWSWIRE) -- From new immunotherapy approaches to insights into environmental ....
Edit

Bladder Cancer Advocacy Network Discusses Why Bladder Cancer Demands Attention Now with YourUpdateTV

Nasdaq Globe Newswire 15 May 2026
Nationwide media tour conducted by Bladder Cancer Advocacy Network in conjunction with D S Simon Media. Nationwide media tour conducted by Bladder Cancer Advocacy Network in conjunction with D S Simon Media ... .
Edit

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, ...

News Graphic 15 May 2026
More than 90% of patients surveyed who underwent bladder ...
Edit

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

Business Wire 15 May 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer ... .
Edit

What To Know About The Latest Treatments For Bladder Cancer (Henry Ford Health System)

Public Technologies 15 May 2026
) Posted on May 15, 2026 by Henry Ford Health Staff 4977 In the United States, bladder cancer is one of the most common cancers of the ...
Edit

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment (Genentech Inc)

Public Technologies 15 May 2026
Adults with a type of bladder cancer called muscle-invasive bladder cancer (MIBC) that has spread into the muscle layer of the bladder but not to other parts of the body ... for their bladder cancer.
Edit

IMFINZI® (durvalumab) regimen reduced early disease recurrence among high-risk non-muscle-invasive bladder cancer patients in POTOMAC Phase III trial exploratory analyses (AstraZeneca Pharmaceuticals LP)

Public Technologies 15 May 2026
"Nearly 40 percent of patients with high-risk non-muscle-invasive bladder cancer who relapse become unresponsive to BCG therapy and face a higher likelihood of bladder removal surgery ... Bladder cancer ... What is bladder cancer? Available at.
Edit

AstraZeneca’s Imfinzi combo lifts survival in bladder cancer trial

Sowetan Live 14 May 2026
AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.
Edit

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

PR Newswire 14 May 2026
JNJ) in collaboration with the International Bladder Cancer Group (IBCG), the World Bladder Cancer Patient Coalition (WBCPC), and the Bladder Cancer Advocacy Network (BCAN), and examined the ...
Edit

Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial (AstraZeneca plc)

Public Technologies 14 May 2026
Together with NIAGARA and POTOMAC, VOLGA is our third positive readout in bladder cancer, setting a strong foundation for Imfinzi as the immunotherapy backbone in this early-stage, curative-intent setting."​ ... Bladder cancer ... Bladder Cancer.
Edit

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial (AstraZeneca Pharmaceuticals LP)

Public Technologies 14 May 2026
Together with NIAGARA and POTOMAC, VOLGA is our third positive readout in bladder cancer, setting a strong foundation for IMFINZI as the immunotherapy backbone in this early-stage, curative-intent setting."​ ... Bladder cancer ... Bladder Cancer.
Edit

BHU team develops non-invasive urine test for bladder cancer

The Times of India 07 May 2026
Comments. +Text SizeSmallMediumLarge. .
Edit

Youngstown man first in WNY to get new bladder cancer treatment

Niagara Gazette 06 May 2026
Ray Page thought he was getting checked for an enlarged prostate ... .

Article Search

tools
×
×
×
×